We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+27.07%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$39.1B
AUM Growth
+$5.57B
(+17%)
Cap. Flow
-$1.33B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
25.2%
Holding
834
New
111
Increased
262
Reduced
309
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$2.28B |
| 2 |
Otis Worldwide
OTIS
|
+$193M |
| 3 |
Burlington
BURL
|
+$191M |
| 4 |
AbbVie
ABBV
|
+$178M |
| 5 |
Wayfair
W
|
+$144M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Lockheed Martin
LMT
|
+$339M |
| 3 |
Johnson & Johnson
JNJ
|
+$262M |
| 4 |
Pfizer
PFE
|
+$167M |
| 5 |
Target
TGT
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.52% |
| 2 | Healthcare | 19.78% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Financials | 11.33% |
| 5 | Industrials | 8.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Booking.com
BKNG
$149B
| $75.2M | 0.19% |
1,180,000
-12,500
| -1% | -$761K |
|
127
Freeport-McMoran
FCX
$91.5B
| $74.6M | 0.19% |
6,445,000
+4,775,000
| +286% | +$43.8M |
|
128
Sherwin-Williams
SHW
$86B
| $74.3M | 0.19% |
385,980
-558,276
| -59% | -$101M |
|
129
Honeywell
HON
$78.2B
| $73.8M | 0.19% |
541,428
-995,934
| -65% | -$132M |
|
130
Colgate-Palmolive
CL
$71.9B
| $72.5M | 0.19% |
989,120
+11,900
| +1% | +$845K |
|
131
Kimberly-Clark
KMB
$35.7B
| $72.4M | 0.19% |
512,323
-199,632
| -28% | -$27.6M |
|
132
Equinix
EQIX
$102B
| $71.8M | 0.18% |
102,268
+5,100
| +5% | +$3.45M |
|
133
L3Harris
LHX
$51.7B
| $71.3M | 0.18% |
420,325
+206,596
| +97% | +$38.8M |
|
134
Saic
SAIC
$5.08B
| $71.2M | 0.18% |
916,588
+370,074
| +68% | +$30.3M |
|
135
Advanced Micro Devices
AMD
$790B
| $71M | 0.18% |
1,348,800
-194,100
| -13% | -$10.3M |
|
136
Owens Corning
OC
$11.5B
| $70.9M | 0.18% |
1,271,731
+202,864
| +19% | +$9.46M |
|
|
HI
137
DELISTED
Hillenbrand
HI
| $70.7M | 0.18% |
2,610,735
+953,133
| +58% | +$21.6M |
|
|
138
Target
TGT
$67.8B
| $69.4M | 0.18% |
579,008
-1,237,961
| -68% | -$141M |
|
|
MNTA
139
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $68.2M | 0.17% |
2,050,000
-70,000
| -3% | -$2.23M |
|
140
Stryker
SYK
$131B
| $67.3M | 0.17% |
373,274
-145,700
| -28% | -$26.9M |
|
141
Olin
OLN
$2.12B
| $66.9M | 0.17% |
5,819,782
-1,350,000
| -19% | -$17.2M |
|
142
Arthur J. Gallagher & Co
AJG
$63.7B
| $66.4M | 0.17% |
681,003
-199,697
| -23% | -$17.7M |
|
143
CF Industries
CF
$18.2B
| $66M | 0.17% |
2,345,542
-904,100
| -28% | -$25.7M |
|
144
Zoetis
ZTS
$32.3B
| $65.8M | 0.17% |
480,389
-8,900
| -2% | -$1.16M |
|
145
Dover
DOV
$27.7B
| $65.6M | 0.17% |
679,484
-1,094,065
| -62% | -$101M |
|
146
Louisiana-Pacific
LPX
$5.15B
| $65.2M | 0.17% |
2,541,730
-1,256,986
| -33% | -$26.6M |
|
147
CME Group
CME
$95.7B
| $64.7M | 0.17% |
398,031
+5,400
| +1% | +$968K |
|
148
Goldman Sachs
GS
$303B
| $63.2M | 0.16% |
319,800
-64,400
| -17% | -$12.1M |
|
149
Illumina
ILMN
$30B
| $63.1M | 0.16% |
175,045
+99,824
| +133% | +$32.1M |
|
150
Karyopharm Therapeutics
KPTI
$44.6M
| $61.5M | 0.16% |
216,583
-31,652
| -13% | -$9.36M |
|
Similar funds
Adage Capital Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Adage Capital Partners held 834 positions worth $39.1B, up 17% from $33.5B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Adage Capital Partners withdrew a net $1.33B in Q2 2020, closing 110 positions and reducing 309 holdings. Its most notable exit was Allergan plc, an estimated $1.66B position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Royalty Pharma worth $2.23B.
- Adage Capital Partners's largest Q2 2020 buy was Royalty Pharma: 46,015,330 shares worth $2.23B.
- Adage Capital Partners added most to Burlington in Q2 2020, an estimated $191M increase.
- Adage Capital Partners's biggest Q2 2020 reduction was Lockheed Martin, cutting an estimated $339M.
- Adage Capital Partners fully exited Allergan plc in Q2 2020, selling an estimated $1.66B.
- Adage Capital Partners's ten largest holdings make up 25% of its $39.1B portfolio in Q2 2020.
- Adage Capital Partners opened 111 new positions and closed 110 in Q2 2020.
- Adage Capital Partners's portfolio value rose 17% quarter-over-quarter to $39.1B.
Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.